News Celgene MS pill can't beat older rival on disability progres... Phase 3 trial meets main efficacy endpoint, but disability progression stats cause concern.
News Novartis cues up Cosentyx as disease-modifying treatment for... Pharma begins early intervention trial after Cosentyx shows "disease modifying" properties
GlaxoSmithKline GSK's new CEO Walmsley paid 25% less than predecessor Witty GlaxoSmithKline (GSK) has confirmed rumours that its incoming CEO Emma Walmsley will be paid less than her predecessor, Sir Andrew Witty.
News Next gen psoriasis drugs show superiority to Stelara Guselkumab can also be used if older drug Stellara fails.
News Celgene files AML pill after fast-track trial The FDA has accepted Celgene’s filing for enasidenib.
Views & Analysis Orphan drugs will fuel pharma's future - and a pricing pushb... Evaluate predicts sales could approach $8bn if approved.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
